CTLA4 and melanoma: In 2011, the U.S. Food and Drug Administration (FDA) approved the CTLA-4 inhibitor ipilimumab for the treatment of advanced melanoma, marking the first significant clinical breakthrough for immune checkpoint inhibitors (77).